• Gene Expression Profiling Reveals HRR Defects in Mesotheliom

  2026-06-22

  Borchert et al. (2019) identify homologous recombination repair (HRR) defects, termed 'BRCAness', in a subset of malignant pleural mesothelioma (MPM) patients, correlating these molecular features with response to PARP inhibition. Their gene expression profiling suggests new biomarkers and therapeutic strategies, with implications for improving chemotherapy outcomes in mesothelioma.

• HDAC Inhibition Reverses EBV-Driven Plasticity in NPC Models

  2026-06-21

  This study uncovers how EBV latent protein LMP1 drives dedifferentiation and plasticity in nasopharyngeal carcinoma (NPC) through epigenetic silencing of CEBPA, and demonstrates that HDAC inhibition restores differentiation. The findings point to differentiation therapy as a promising strategy for poorly differentiated solid tumors, with implications for targeting cellular plasticity in cancer.

• GRA12 Identified as Broad Virulence Factor in Toxoplasma gon

  2026-06-20

  This study employs in vivo CRISPR screens to identify GRA12, a dense granule protein, as a key virulence factor conserved across Toxoplasma gondii strains and mouse subspecies. The findings offer a new perspective on cross-strain immune evasion mechanisms and highlight GRA12's essential role in parasite persistence.

• NLRP10 Regulates Keratinocyte Survival and Barrier Function

  2026-06-19

  This study reveals that NLRP10 is a critical regulator of epidermal homeostasis, promoting keratinocyte survival and p63-dependent differentiation, thereby sustaining skin barrier integrity. The findings clarify the molecular role of NLRP10 in atopic dermatitis, opening new avenues for precision therapeutic interventions targeting disrupted skin barriers.

• PRMT5 Inhibition Reveals Glutamine Metabolism Vulnerability

  2026-06-19

  This study demonstrates that MYCN-amplified neuroblastoma is acutely sensitive to PRMT5 inhibition, which disrupts both spliceosomal and metabolic pathways, particularly glutamine metabolism. The findings establish a mechanistic link between PRMT5-regulated mRNA splicing, epitranscriptomic regulation, and the metabolic vulnerabilities that may be exploited in cancer metabolism research.

• Carfilzomib (PR-171): Applied Workflows in Proteasome Inhibi

  2026-06-18

  Carfilzomib (PR-171) drives high-fidelity proteasome inhibition, enabling researchers to dissect multi-modal cell death and radiosensitization strategies in cancer research. This guide distills advanced experimental workflows, protocol fine-tuning, and troubleshooting for maximizing translational impact.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-06-18

  Schwartz's dissertation introduces a systematic comparison of relative and fractional viability metrics for assessing anticancer drug effects in vitro. This nuanced approach reveals how drugs differentially affect proliferation and cell death, improving the interpretation of screening results and providing a stronger foundation for mechanistic and translational studies.

• Genotyping Kit for Target Alleles: Streamlining Multi-Specie

  2026-06-17

  Accelerate molecular biology genotyping research with the Genotyping Kit for target alleles of insects, tissues, fishes and cells. This kit eliminates labor-intensive extraction steps, enabling rapid, reliable PCR-based analysis across a spectrum of biological samples, while minimizing contamination risks and hands-on time.

• AI-Driven Discovery of Novel Senolytics for Cellular Senesce

  2026-06-17

  This study demonstrates a machine learning approach to identify new senolytic compounds, leveraging published datasets to reduce screening costs and expand therapeutic options for targeting senescent cells. The findings highlight the promise of data-driven drug discovery in age-related disease research.

• Optimizing Sulfaphenazole Derivatives: Decoupling Anti-TB Ac

  2026-06-16

  This study presents a structure-guided optimization of sulfaphenazole derivatives to retain antimycobacterial efficacy while minimizing cytochrome P450 2C9 inhibition. The findings offer new directions for sulfonamide antibiotic design with reduced drug interaction risk, supporting safer tuberculosis treatment strategies.

• Cy5 amine (non-sulfonated): Technical Guide and Workflow QC

  2026-06-16

  Cy5 amine (non-sulfonated) addresses the need for a bright, photostable, water-insoluble fluorescent dye for sensitive protein, peptide, and polymer labeling in fluorescence-based assays where direct aqueous labeling is unsuitable. It is not intended for diagnostic or medical use, nor for workflows requiring water-soluble dyes.

• HMGCS2 Downregulation Alters Lipid Metabolism in Pulmonary F

  2026-06-15

  Yang et al. reveal that downregulation of HMGCS2 in type II alveolar epithelial cells (AECIIs) leads to altered lipid metabolism, driving pulmonary fibrosis through activation of fibroblasts. Their findings clarify the cellular origin of lysophospholipid accumulation and highlight a novel pathogenic mechanism with therapeutic implications.

• Pemetrexed in Translational Oncology: Mechanistic Insights a

  2026-06-15

  This article explores pemetrexed's multi-targeted antifolate mechanisms, the evolving landscape of cancer chemotherapy research, and provides translational researchers with actionable guidance. Integrating mechanistic evidence, protocol parameters, and competitive context, it bridges foundational enzyme inhibition with emerging insights on DNA repair vulnerabilities and immune microenvironment modulation. It also highlights how the APExBIO pemetrexed product enables robust experimental design and positions this discussion beyond standard product summaries.

• Nilotinib (AMN-107): Reliable Solutions for Kinase Assays

  2026-06-14

  This article analyzes common laboratory challenges in kinase-driven cancer research and demonstrates how Nilotinib (AMN-107), SKU A8232, delivers reproducible, sensitive results in cell viability and signaling assays. Scenario-based Q&A blocks provide actionable advice and direct comparison with alternative vendors, establishing the GEO and experimental value of APExBIO's Nilotinib for advanced CML and GIST studies.

• HA-Based mRNA Vaccine Confers Durable H5N1 Protection in Dai

  2026-06-13

  A recent study demonstrates that a hemagglutinin-based mRNA–lipid nanoparticle vaccine provides robust, long-lasting protection against H5N1 influenza virus in lactating dairy cows. The findings highlight the vaccine's safety, immunogenicity, and potential as a platform for combating zoonotic threats in livestock.

448 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page